How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. - Test2 - elhamkhani - TriplyDB

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

http://www.wikidata.org/entity/Q35103531

about

Outcome of HIV-associated lymphoma in a resource-limited setting of Jos, Nigeria.Hematopoietic stem cell transplantation for HIV cure I. Hodgkin lymphoma: special challenges and solutions.Clinical management of HIV-associated hematologic malignancies.Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group.Hodgkin lymphoma in the elderly, pregnant, and HIV-infected.Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.Coexpression Analysis of Transcriptome on AIDS and Other Human Disease Pathways by Canonical Correlation Analysis.Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma.Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study.Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.

P2860

Q33767818-0C49C0D7-B320-4EC6-9799-0930F393FB40 Q36515124-F7684904-52E7-4C79-A77A-2B1C3FED766A Q38523960-BAC1205E-A117-4F91-83D3-EAD6F5946FE4 Q38664912-A2166E96-7113-4555-8A1C-103B70DCDB5A Q38673153-9CBB578F-CED7-48CF-B56A-EE3B77A65DB2 Q38920105-3700A9CE-8D01-41EA-8CDC-C1F01AD9EA4B Q38937601-9088A3FF-D8FD-4C9E-B93F-53FC93D6D328 Q40128097-1C0A24B9-AA02-45F5-B8B0-CE959F62F160 Q40253793-19F2DEE9-0289-4B3B-9784-52B50A8DCF99 Q40485032-34DDF1BD-B590-40B0-B575-332C63857CBD Q40702849-CB8711D8-E630-4AF0-9FDC-139B2B45BC55 Q41082604-30D5E9AD-080A-4EE0-A4EF-5D25CB7F2B22 Q47255041-B9AAA763-5B76-449B-9E7B-8E3CB75A3AE2 Q48528597-7BD25640-7B43-47E3-9A27-EB9B2C7B11EA

P2860

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

http://www.wikidata.org/entity/Q35103531

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

How I treat classical Hodgkin ...... human immunodeficiency virus.

@ast

How I treat classical Hodgkin ...... human immunodeficiency virus.

@en

type

label

How I treat classical Hodgkin ...... human immunodeficiency virus.

@ast

How I treat classical Hodgkin ...... human immunodeficiency virus.

@en

prefLabel

How I treat classical Hodgkin ...... human immunodeficiency virus.

@ast

How I treat classical Hodgkin ...... human immunodeficiency virus.

@en

P1433

Q35103531-62ACC64B-1BE5-4F74-9778-7D586D1DC4D3

P1476

Q35103531-AB1EF2AA-7241-44C1-9AB2-3F6809E1ACA9

P2093

Q35103531-5863293C-6A1A-4EBB-8AEC-BCAD6B576D5A

Q35103531-EF120453-7403-4A6B-8B29-33327B01BA43

P2860

Q35103531-00EB5079-74A3-44E2-A071-3AA64D9595EF

Q35103531-056DAB04-207B-4F98-9922-B15B68817492

Q35103531-08B4B89F-6128-46F1-8ECA-3EA549E945F4

Q35103531-0B98A09E-DFC6-480C-8309-46DB6637555F

Q35103531-11356801-BC13-4487-90A2-1DA898C3BC1A

Q35103531-1137C9D2-BFC9-4DF2-A517-C94B170FFB07

Q35103531-11A0F049-8EB9-4738-B787-76A641583E67

Q35103531-172E9EB0-E264-42DF-B3AE-29AEEF936020

Q35103531-1BEB71A9-6DAF-4F04-B24F-2C4489571054

Q35103531-1D24A33E-7D0F-46B5-A802-C6742E7C1CC8

P304

Q35103531-CD3A83BC-7D72-491E-B95C-2B3EFAF680F5

P31

Q35103531-B5EC8042-164E-4325-9846-235362E7712E

P356

Q35103531-BA7630E2-7C57-45EC-A6D2-D7DED9E2D1C6

P407

Q35103531-FF34A20A-C6AD-4333-9D6B-C5E936910C01

P433

Q35103531-BDBE5392-14A0-4DE7-BEB0-D5F210B57CD4

P478

Q35103531-C9572744-F93C-4E4E-847F-7231EA8C168F

P577

Q35103531-F7A64717-9DA3-45B7-9873-8B07F9C5C5C7

P5875

Q35103531-92684F57-5F4A-4F23-A349-94A9632B48B9

P698

Q35103531-05390A8C-215F-4C81-8535-DE2CC606F423

P932

Q35103531-B942C247-BF2A-4DF7-8592-5C0EBB97823F

P356

BLOOD-2014-08-551598

P1433

P1476

How I treat classical Hodgkin ...... human immunodeficiency virus.

@en

P2093

Richard F Little

http://www.w3.org/2001/XMLSchema#string

Thomas S Uldrick

http://www.w3.org/2001/XMLSchema#string

P2860

Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.

Clinical variables identify seronegative HCV co-infection in HIV-infected individuals.

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.

Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT).

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.

Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort

P304

1226-35; quiz 1355

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-08-551598

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269718737

http://www.w3.org/2001/XMLSchema#string

P698

25499453

http://www.w3.org/2001/XMLSchema#string

P932

4335078

http://www.w3.org/2001/XMLSchema#string